Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma

Hepatology

Volumn 55, Issue 6, 2012, Pages 1754-1765

  Liu, Ming ^a   Chen, Leilei ^a   Chan, Tim Hon Man ^a   Wang, Jian ^a   Li, Yan ^a,b   Zeng, Ting Ting ^b   Yuan, Yun Fei ^b   Guan, Xin Yuan ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 8Q; CLONOGENESIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE ACTIVATION; GENE AMPLIFICATION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENOMIC FRAGMENT; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 8; CYCLIN D1; G1 PHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LIVER NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; S PHASE;

EID: 84861574782     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25584     Document Type: Article

References (36)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285.
2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346.
3. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3: 573-588.
4. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997; 14: 2927-2933.
5. Parada LA, Hallen M, Tranberg KG, Hagerstrand I, Bondeson L, Mitelman F, et al. Frequent rearrangements of chromosomes 1, 7, and 8 in primary liver cancer. Genes Chromosomes Cancer 1998; 23: 26-35.
6. Santoni-Rugiu E, Jensen MR, Thorgeirsson SS. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res 1998; 58: 123-134.
7. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa A. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 2003; 38: 1242-1249.
8. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma YL, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904.
9. Webster MK, Goya L, Ge Y, Maiyar AC, Firestone GL. Characterization of Sgk, a novel member of the serine threonine protein-kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol Cell Biol 1993; 13: 2031-2040.
10. Kobayashi T, Cohen P. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem J 1999; 339: 319-328.
11. Loffing J, Flores SY, Staub O. SGK kinases and their role in epithelial transport. Annu Rev Physiol 2006; 68: 461-490.
12. Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Second AKT: the rise of SGK in cancer signalling. Growth Factors 2010; 28: 394-408.
13. Liu D, Yang XH, Zhou SY. Identification of CISK, a new member of the SGK kinase family that promotes IL-3-dependent survival. Curr Biol 2000; 10: 1233-1236.
14. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009; 16: 21-32.
15. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
16. Chen R, Zhu D, Ye X, Shen D, Lu R. Establishment of three human liver carcinoma cell lines and some of their biological characteristics in vitro. Scientia Sinica 1980; 23: 236-247.
17. Wang JB. Establishment and some characteristics of a hepatoma cell line (QGY-7703). Zhonghua Zhong Liu Za Zhi 1981; 3: 241-244.
18. Tang XH, Qin SK, Chen HY. Increasing anti-tumor effect of arsenic trioxide combining with cisplatin on the QGY-7701 human hepatocarcinoma cells line. J Cancer Prev Treat 2002; 29: 362-364.
19. Zhang M, Wen JM, Xu JM, Wang WS, Hu L, Xie D, et al. [Establishment and cytogenetic characterization of a human hepatocellular carcinoma cell strain from the embolus in portal vein.] Chin J Cancer 2002; 21: 1203-1207.
20. Guan XY, Sham JST, Tang TCM, Fang Y, Huo KK, Yang JM. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 2001; 61: 3806-3809.
21. Fu L, Qin YR, Xie D, Flu L, Kwong DL, Srivastava G, et al. Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell carcinoma. Cancer Res 2007; 67: 10720-10726.
22. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68: 6779-6788.
23. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-947.
24. Diehl JA, Cheng MG, Roussel MF, Sherr CJ. Glycogen synthase kinase 3 beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-3511.
25. Dai FY, Yu L, He H, Chen YJ, Yu JQ, Yang YM, et al. Human serum and glucocorticoid-inducible kinase-like kinase (SGKL) phosphorylates glycogen syntheses kinase 3 beta (GSK-3 beta) at serine-9 through direct interaction. Biochem Biophys Res Commun 2002; 293: 1191-1196.
26. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619-628.
27. Croce CM. Molecular origins of cancer: oncogenes and cancer. N Engl J Med 2008; 358: 502-511.
28. Pulciani S, Santos E, Long LK, Sorrentino V, Barbacid M. Ras gene amplification and malignant transformation. Mol Cell Biol 1985; 5: 2836-2841.
29. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
30. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009; 220: 292-296.
31. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 1994; 91: 709-713.
32. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
33. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769-776.
34. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, et al. AKT1/PKB alpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-437.
35. Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 2000; 85: 160-165.
36. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998; 17: 1557-1565.